Cargando…
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination
Various cancer vaccines have been developed to generate and amplify antigen‐specific T cell responses against malignancy. Among them, in situ vaccination is one of the most practical types as it can trigger immune responses without previous antigen identification. Here we reported a novel in situ va...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586665/ https://www.ncbi.nlm.nih.gov/pubmed/34537997 http://dx.doi.org/10.1111/cas.15145 |